Cocoa

# Research Output: Cocoa (Theobroma cacao)

**Substance:** Cocoa  
**PSX ID:** PSX-0141  
**Research Date:** 2026-05-13  
**Provenance ID:** a758634f-1ba3-4a6e-8292-c39b48de3a96

---

## Botanical Identity

**Accepted binomial:** *Theobroma cacao* L.  
**Authority & first publication:** Carl Linnaeus, *Species Plantarum* (1753), p. 782 [Ref 42]  
**Family:** Malvaceae (subfamily Byttnerioideae) — previously placed in Sterculiaceae before that family was merged into Malvaceae [Ref 27]  
**Genus:** *Theobroma* (Greek: "food of the gods," from *theós* = god + *brôma* = food) [Ref 42]

**Synonyms (selected from 24 documented):** *Cacao minus* Gaertn., *Cacao theobroma* Tussac (nom. illeg.), *Theobroma leiocarpum* Bernoulli, *Theobroma pentagonum* Bernoulli, *Theobroma sphaerocarpum* A.Chev., *Theobroma kalagua* De Wild. [Ref 27]

**Native range:** Costa Rica to South Tropical America — specifically Brazil (North), Colombia, Costa Rica, Ecuador, French Guiana, Guyana, Peru, Suriname, and Venezuela. Originates in lowland rainforests of the Amazon and Orinoco river basins [Ref 27]. Molecular evidence suggests Upper Amazon as the primary domestication center, ca. 5450–5300 BP [Ref 41].

**Cultivation status:** Primarily cultivated. Introduced into numerous tropical regions including West Africa (Cameroon, Ghana, Ivory Coast — now dominant global producers), Southeast Asia (Indonesia, Malaysia, Vietnam), and the Caribbean. Wild populations exist in the Amazon basin but commercial production is entirely from cultivated trees [Ref 27, 41].

**Main cultivar groups:**
- **Criollo** — fine/aromatic type, historically cultivated in Central America (pre-Columbian), thin pod walls, low disease resistance. Highest flavor quality. First cultivated type in Mesoamerica [Ref 14].
- **Forastero (including Amelonado)** — bulk cocoa, Amazon basin origin, more vigorous and disease-resistant. Represents ~80–90% of world production. Used in Trinitario breeding programs from the 1930s–1950s [Ref 14].
- **Trinitario** — natural hybrid of Criollo × Amelonado Forastero; originated in Trinidad; three main genotypes (SP1, MAT1-6, SIAL70) identified in samples from 17 countries [Ref 14].

**Morphological notes:** Small evergreen tree, 6–12 m in cultivation. Pods are cauliflorous (borne directly on the trunk and main branches). Each pod contains 20–50 seeds (cacao beans) embedded in sweet white mucilage. Risk of misidentification with other *Theobroma* species (notably *T. grandiflorum*, cupuassu) is low in commerce but possible in wild-harvested material. *Herrania* species have been confused with *Theobroma* at the genus level historically [Ref 27].

**Discrepancy with seed data:** The brief listed family, genus/species, native range, and cultivation status all as "no seed data." This information has been fully established from authoritative sources above. The brief's type classification of "preparation" may warrant review — *T. cacao* is the source plant, and "cocoa" describes both the plant and its processed preparations.

---

## Alkaloid / Cannabinoid Profile

### Primary Alkaloids

**Theobromine (3,7-dimethylxanthine)**  
PubChem CID: 5429 | Molecular formula: C₇H₈N₄O₂ | MW: 180.16 g/mol | InChIKey: YAPQBXQYLJRXSA-UHFFFAOYSA-N

Dominant methylxanthine in cacao. Quantified concentrations:
- In cocoa bean mucilage (Nacional × Trinitario variety): 2.65% dry weight; Forastero (CCN-51) variety: 1.28% dry weight [Ref 9]
- In artisanal chocolates (36–100% cocoa content): 1.158–21.033 g/kg, with strong positive correlation to declared cocoa percentage [Ref 24]
- Dark chocolate (≥70% cocoa) typically contains approximately 10–18 g theobromine per kg [Ref 24]
- Bioaccessibility from cocoa powder during gastrointestinal digestion (INFOGEST model): >85% [Ref 34]

**Caffeine (1,3,7-trimethylxanthine)**  
PubChem CID: 2519 | Molecular formula: C₈H₁₀N₄O₂ | MW: 194.19 g/mol | InChIKey: RYYVLZVUVIJVGH-UHFFFAOYSA-N

Secondary methylxanthine; theobromine:caffeine ratio typically 10:1 in cocoa.
- Mucilage (Nacional × Trinitario): 0.90% dry weight; CCN-51: 0.35% dry weight [Ref 9]
- In artisanal chocolates: 0.058–1.997 g/kg across 36–100% cocoa content range [Ref 24]
- Theobromine is the discriminating variable for cocoa content authentication; caffeine alone is insufficient [Ref 24]

**Biosynthetic relationship:** Caffeine biosynthesis in *Theobroma* proceeds via xanthosine → 7-methylxanthosine → 7-methylxanthine → theobromine → caffeine. Theobromine is thus a biosynthetic precursor to caffeine in cacao (unlike in *Coffea*, where both accumulate) [Ref 1].

### Secondary Constituents

**Epicatechin and Catechin (flavan-3-ols)**  
Dominant polyphenols. Epicatechin: 13.71 mg/L in mucilage; catechin: 35.44 mg/g in mucilage (Nacional × Trinitario variety). Procyanidins B1, B2, C1 also quantified [Ref 9, 10]. Epicatechin Cmax ~260 nmol/L at Tmax ~1.8h; mean bioavailability from cocoa ~25% [Ref 23].

**Procyanidins (condensed tannins)**  
Oligomeric procyanidins in cocoa beans quantified from monomers through decamers by normal-phase HPLC with fluorescence detection [Ref 10]. Oligomer-rich fractions show the greatest metabolic benefits in animal feeding studies [Ref 3 — OpenAlex W2165116045].

**Phenylethylamine (β-phenylethylamine, PEA)**  
PubChem CID: 1001 | Molecular formula: C₈H₁₁N | MW: 121.18 g/mol  
Present in trace amounts as a biogenic amine; formed during fermentation of cacao beans via microbial amino acid decarboxylation [Ref — biogenic amine review]. Rapid first-pass monoamine oxidase (MAO) metabolism in gut and liver limits systemic bioavailability at typical dietary doses. Its role in chocolate's mood effects is disputed — no published human dose-response studies demonstrate clinically meaningful PEA activity from cocoa consumption.

**N-Acylethanolamines (cannabinoid-related lipids)**  
Three compounds in chocolate — anandamide (N-arachidonoylethanolamine, PubChem CID 5281969), N-oleoylethanolamide, and N-linoleoylethanolamide — were identified by di Tomaso et al. (1996) [Ref 17]. These compounds can act as cannabinoid mimics (direct CB1 activation) or indirectly by inhibiting anandamide hydrolase (FAAH), thereby prolonging anandamide's activity [Ref 17]. **However:** A forensic investigation confirmed that these N-acylethanolamines in chocolate do not cross-react with standard cannabis immunoassay screening tests, demonstrating insufficient concentrations for clinically meaningful cannabinoid effects at dietary doses [Ref 18]. Early commentary estimated that a 130-pound person would need to consume ~25 lbs of chocolate to achieve any marijuana-like effect [Ref 19]. ⚠️ **FLAG:** The endocannabinoid hypothesis for chocolate psychoactivity remains unconfirmed by human clinical studies; traditional-use accounts and in vitro data are the primary evidence.

### Preparation Effects on Constituent Ratios

- **Fermentation:** Essential step post-harvest; dramatically alters flavanol and alkaloid profiles. Reduces astringency; theobromine and caffeine concentrations are relatively stable through fermentation vs. raw pulp [Ref 38]. Biogenic amines including phenylethylamine and tyramine are produced during fermentation [Ref — biogenic amine review].
- **Roasting:** Higher temperatures (110–150°C) decrease soluble free phenolics (SFPs) and increase bound phenolics in melanoidin fractions. Criollo beans (unroasted) have the highest SFP content; roasting at 150°C maximizes bound phenolics. Roasting does not significantly alter methylxanthine content [Ref 39].
- **Dutch/alkali processing:** Significantly reduces flavanol content in cocoa powder; heavily Dutched cocoa may lose the majority of its epicatechin content. Not directly confirmed in retrieved papers but referenced in manufacturing review [Ref 32].
- **Chocolate manufacturing:** Dark chocolate preserves more flavanols than milk chocolate; milk proteins can bind epicatechin and reduce bioavailability [Ref 32]. Theobromine from cocoa methylxanthines increases co-ingested epicatechin bioavailability by +21% (Cmax) in humans — demonstrating a synergistic interaction between cocoa constituents [Ref 22].

---

## History & Ethnobotany

**Origin:** The Upper Amazon basin is the center of origin for *Theobroma cacao* [Ref 41]. Molecular analyses support origin in the periphery of Amazonia with pre-Columbian dispersal northward [Ref 41]. The species was likely brought into domestication in Mesoamerica from Amazonian wild populations, though incipiently domesticated Amazonian populations may also exist [Ref 41].

**Archaeological evidence:** Chemical residues of cacao (identified by HPLC-APCI-MS detection of theobromine) were found in spouted ceramic vessels at the Maya site of Colha, northern Belize, dating to ~600 BCE — pushing the earliest chemical evidence of cacao use back ~1,000 years from previous estimates [Ref 13]. This is the earliest confirmed human use of cacao in the archaeobotanical record.

**Mesoamerican use:** Cacao cultivation reached Mesoamerica 3,800–3,000 BP [Ref 41]. It was used by the Olmec, Maya, and Aztec civilizations as a ceremonial and dietary beverage. The Maya prepared "xocolatl" (bitter water in Nahuatl/Aztec tradition) as a frothy, unsweetened drink. Cacao beans also served as currency in Aztec society. Classic Maya cylinder vessels have been interpreted as cacao-drinking vessels based on hieroglyphic inscriptions and residue analysis, though the interpretation of specific vessel functions remains debated in the literature [Ref — OpenAlex W2810541362]. ⚠️ **FLAG for human review:** Traditional ceremonial use accounts are the primary evidence for pre-colonial ritual context; clinical confirmation of psychoactive effects from traditional preparations is absent.

**History of cultivation and disease:** Cacao cultivation intensified during the colonial period (post-1500s) in Mesoamerica, Trinidad, Venezuela, and Ecuador. The collapse of the Trinidad cacao industry in the 1720s ("blast" disease) and the later introduction of witches' broom to Bahia, Brazil (late 1980s) shifted production to West Africa, now the dominant production region [Ref 41].

**European introduction:** Spanish explorers introduced cacao to Europe in the 1520s following contact with Mesoamerican civilizations [Ref 42]. By the mid-17th century, chocolate houses were established across Europe among the elite. Demand led France to establish Caribbean plantations and Spain to develop Venezuelan and Philippine cacao cultivation [Ref 42].

**Scientific description:** Carolus Linnaeus formally described and named *Theobroma cacao* in *Species Plantarum* in 1753, using the genus name *Theobroma* (Greek: "food of the gods") [Ref 27, 42].

**Pharmaceutical interest timeline:** Theobromine isolated from cacao in the 1840s (Woskresensky, 1841 — per secondary sources; unverifiable via API). Clinical interest in flavanols began in the 1990s following observations in the cardiovascular-healthy Kuna Indian population of Panama [Ref 35]. Formal clinical trial programs (COSMOS, COSMOS-Mind) launched in the 2010s [Ref 5, 43].

---

## Neuroscience & Mechanism

### Primary Receptor Targets

**Adenosine receptor antagonism (theobromine and caffeine)**  
Theobromine antagonizes both A₁ and A₂A adenosine receptors in hippocampal synapses [Ref 2]. At a physiologically relevant concentration (30 μM), theobromine:
- Facilitates synaptic transmission via A₁R blockade
- Impairs long-term potentiation (LTP) via A₂AR blockade
- Provides neuroprotection against Aβ₁₋₄₂ peptide-induced neuronal loss (relevant to Alzheimer's) [Ref 2]

Caffeine shares the same receptor targets but is present at lower concentrations in cocoa. The methylxanthines in coffee and cacao (caffeine, theobromine) promote sustained cognitive performance and protect neurons in animal models of stroke, Alzheimer's, and Parkinson's disease via adenosine receptor antagonism [Ref 3].

**Phosphodiesterase (PDE) inhibition**  
Both theobromine and caffeine inhibit phosphodiesterases, preventing cAMP and cGMP breakdown. This increases intracellular cAMP → protein kinase A activation → downstream effects on glucose metabolism, heart rate, and smooth muscle relaxation [Ref 15, 16].

**Nitric oxide production (epicatechin/flavanols)**  
Cocoa flavanols (primarily epicatechin and its metabolites) stimulate endothelial nitric oxide synthase (eNOS), increasing NO production → vasodilation → improved blood flow [Ref 35]. This is the primary mechanism for flavanol-mediated cardiovascular benefits. This mechanism is distinct from and additive to the methylxanthine pathway [Ref 35].

**Sensory nerve inhibition (theobromine — antitussive)**  
In a randomized, double-blind, placebo-controlled human trial, theobromine suppressed capsaicin-induced cough with no adverse effects. The mechanism appears to be peripheral inhibition of capsaicin-induced sensory nerve depolarization of the vagus nerve [Ref 28]. This is a clinically distinct mechanism from adenosine receptor blockade.

**Platelet aggregation inhibition (theobromine)**  
Pre-incubation of platelets with theobromine attenuates ADP- and TRAP6-induced platelet aggregation independently of flavanol content [Ref 4]. This flavanol-independent effect occurs via a mechanism still under investigation.

### Pharmacokinetics of Primary Constituents

**Theobromine:**
- Oral bioavailability: high (>85% bioaccessibility from cocoa matrix) [Ref 34]
- Metabolized via N-demethylation; caffeine is metabolized via CYP1A2 to paraxanthine (major), theobromine, and theophylline [Ref 1]. CYP1A2 is the primary enzyme for caffeine metabolism; theobromine itself is further demethylated to xanthine and uric acid
- Half-life in humans: approximately 6–10 hours (referenced in secondary reviews [Ref 15, 16]; no primary PK study retrieved from APIs for theobromine alone — ⚠️ FLAG)
- Dose-dependent nonlinear metabolism: caffeine clearance decreases significantly with increasing dose, leading to disproportionate accumulation of methylxanthines [Ref — PMID 2401126]

**Epicatechin (flavan-3-ol):**
- Two absorption Cmax peaks: ~260 nmol/L at ~1.8h (small intestine) and ~88 nmol/L at ~5.3h (colonic microbial metabolites) [Ref 23]
- Mean bioavailability from cocoa: ~25%; from pure epicatechin: ~82% [Ref 23]
- Theobromine co-ingestion increases epicatechin Cmax by +21% in humans [Ref 22]
- Extensively metabolized by colonic microbiota to phenyl-γ-valerolactones and phenylvaleric acids [Ref 23]

**CYP involvement:** Caffeine is primarily metabolized by CYP1A2. Inhibition or induction of CYP1A2 (by other drugs, smoking, or diet) will alter caffeine (and by extension, theobromine formation) metabolism. No direct CYP interaction study for theobromine specifically was retrieved — ⚠️ FLAG.

---

## Effects & Dose by Preparation

⚠️ **Critical Gap:** No published dose-response studies characterizing psychoactive dose tiers (threshold/common/heavy) for cocoa as a whole preparation exist in the retrieved literature. The pharmacologically active components (theobromine, caffeine, epicatechin) have been studied individually or in standardized extracts, but not as preparation-specific dose tiers. All dose data below are **flagged for human review** and should not be presented as established dose ranges.

### Cocoa Powder (oral, hot drink)
- Standard commercial serving: ~5–15g cocoa powder
- At 15g serving: approximately 150–300mg theobromine, 10–30mg caffeine (estimates based on HPLC data) [Ref 24]
- Effects: mild stimulation, wakefulness, mood improvement at typical dietary doses
- Onset: ~30–60 min for methylxanthine effects; flavanol cardiovascular effects within ~2h [Ref 4, 35]

### Dark Chocolate (oral, solid)
- 100g dark chocolate (70–85% cocoa): approximately 400–800mg theobromine, 40–80mg caffeine [Ref 24]
- In human RCTs, 85% dark chocolate (1 mg/g body weight) increased systolic BP ~5% at rest 2h post-ingestion, while buffering cardiovascular reactivity during acute mental stress [Ref — PMID 31526307]
- Sub-chronic daily consumption for 30 days: increased plasma theobromine, elevated NGF, improved cognitive performance on Stroop and cancellation tests [Ref 11]

### Standardized Cocoa Flavanol Extract (oral supplement, clinical trial doses)
- COSMOS-Mind trial: 500 mg/day cocoa flavanols [Ref 43]
- Cardiovascular studies: 600–1350mg flavanols/day (acute) [Ref 5 — COSMOS RCT]
- Flow-mediated dilation studies: 150mg flavanols (acute, single dose) improved FMD and blunted mental stress-induced endothelial dysfunction [Ref — PMID 33801767]

### Dose-Response Characterization
- **Cardiovascular:** Cochrane meta-analysis: 2 mmHg systolic BP reduction from flavanol-rich cocoa vs low-flavanol control (moderate quality evidence) [Ref 29]
- **Cognition:** COSMOS-Mind tested 500mg/day flavanols; results pending extraction [Ref 43]
- **Effect modifiers:** Cultivar (Criollo higher flavanol than Forastero), processing method (Dutch processing sharply reduces flavanols), food matrix (milk reduces epicatechin bioavailability), individual CYP1A2 polymorphisms, age, and baseline cardiovascular status [Ref 18 — cross-reference; Ref 32]

### Subjective Effects from Controlled Studies
- Mild mood improvement and alertness consistently attributed to methylxanthine content [Ref 15]
- No controlled human studies demonstrating specific subjective psychoactive effects (e.g., euphoria, disinhibition) at typical dietary doses — ⚠️ FLAG for community feedback effects listed in brief

---

## Safety & Toxicity

### Toxicology Data

**Theobromine in humans:** Considered safe at typical dietary exposures. In comparative acute oral toxicity studies (per OECD guidelines), theobromine at 2000 mg/kg caused 66.6% mortality in mice and 33.3% in rats [Ref 7]. No human LD50 data from published primary research was retrieved — ⚠️ FLAG (secondary sources estimate human LD50 ~1000 mg/kg, but this could not be api-verified).

**Theobromine in rabbits (teratogenicity):** Exposure of 200 mg/kg/day by gavage approximated the maternal LD50 in New Zealand White rabbits. At 125–200 mg/kg/day, fetal weight decreases and skeletal malformations were observed. Dietary exposure at ≤63 mg/kg/day showed no fetotoxicity or teratogenicity. The highest dietary doses tested were 38× the estimated maximum human consumption [Ref 8].

**Theobromine in dogs:** Species-specific sensitivity: theobromine is eliminated much more slowly in dogs than in humans. A case of chocolate toxicity in a dog (Corgi, 88.3 mg/kg body weight ingested) produced severe tachycardia, tremors, seizures, near-arrest, and prolonged neurological sequelae [Ref 40]. This reflects fundamental differences in theobromine metabolism between species — dogs lack efficient N-demethylation capacity [Ref 15].

**Caffeine dose-dependent nonlinear kinetics:** Caffeine clearance decreases at higher chronic doses, causing disproportionate accumulation; this is a mechanism proposed for nonlinear health risks at high habitual coffee intake [Ref — PMID 2401126].

### Case Reports of Adverse Events

No published case reports of human hospitalizations or fatalities from dietary cocoa/chocolate consumption at normal intake levels were identified in the retrieved literature. The primary published safety concern in humans at typical doses is:
1. Cadmium/lead contamination (see Contaminants below)
2. Caffeine-related adverse effects at high intake (e.g., insomnia, tachycardia, anxiety)

### Psychological Risks

- **Anxiety:** High caffeine intake (which can be achieved with heavy dark chocolate consumption) can produce anxiety, insomnia, and tremor. Dose-dependent; individual variation based on CYP1A2 polymorphisms and adenosine receptor sensitivity
- **No psychotomimetic risk** at typical dietary doses has been documented. The endocannabinoid-mimic hypothesis (di Tomaso et al. 1996) has not been confirmed in human behavioral studies [Ref 17, 18, 19]
- **"Chocolate craving"** is documented in the literature as a real behavioral phenomenon; however, whether this reflects pharmacological reinforcement (theobromine/caffeine), nutritional need, or conditioned learned response remains contested [Ref — PMID 29065193 context; see Gaps]

### Herb-Drug Interactions

⚠️ **FLAG — low confidence:** No published case reports of clinically significant herb-drug interactions specifically from dietary cocoa were retrieved via API search. The following theoretical interactions are pharmacologically plausible but not backed by published clinical case reports:

1. **MAOI + chocolate tyramine (pharmacodynamic):** MAO inhibitors reduce first-pass metabolism of dietary tyramine and phenylethylamine. Chocolate contains trace tyramine and phenylethylamine from fermentation [Ref — biogenic amine review]. This could theoretically precipitate a hypertensive crisis in patients on irreversible MAOIs (phenelzine, tranylcypromine). However, no published case reports specifically implicating cocoa/chocolate in MAOI hypertensive crises were identified. **Flag for human editorial review.**

2. **Caffeine + adenosine analogues (pharmacodynamic antagonism):** Caffeine/theobromine oppose the effects of therapeutic adenosine (e.g., adenosine used in cardiac testing). No cocoa-specific case reports retrieved.

3. **Flavanols + CYP3A4/P-glycoprotein (pharmacokinetic):** Epicatechin metabolites may modulate drug-metabolizing enzymes in vitro [Ref 23]; clinical significance at dietary doses unestablished.

**Interaction severity: cannot be rated without clinical case reports or primary PK mechanism studies** — ⚠️ Flag for human review.

### Tolerance and Dependence

**Caffeine tolerance:** Tolerance to the subjective and sleep-disrupting effects of caffeine develops with repeated use; demonstrated across multiple human studies [Ref 20]. Tolerance may develop to cocoa's stimulant effects at heavy habitual consumption.

**Caffeine physical dependence and withdrawal:** Well-established for caffeine-containing beverages generally:
- Withdrawal onset: ~12–24 hours after last dose
- Peak symptoms: days 1–2
- Resolution: 5–7 days
- Symptoms: headache (most common), fatigue/sleepiness, irritability, decreased alertness, flu-like symptoms
- Minimum dose to produce dependence: as low as 100 mg/day
- DSM-IV dependence criteria met in 9–30% of heavy caffeine users [Ref 20, 21]

Whether cocoa-specific consumption (given lower caffeine content relative to coffee) produces a clinically meaningful dependence syndrome has not been studied — ⚠️ FLAG. The caffeine content of a typical dark chocolate serving (~50-80mg) is below that of coffee (~95mg) but above threshold for dependence with daily heavy consumption.

**Theobromine dependence:** No dependence syndrome or withdrawal phenomenon specific to theobromine has been documented in published literature. Theobromine has fewer CNS effects and lower reinforcing potential than caffeine [Ref 15].

### Contaminant and Adulterant Risks

**Cadmium (Cd):** The most serious safety concern for commercial cocoa. Cacao plants bioaccumulate cadmium from soil, particularly in Latin American production regions (Peru, Ecuador, Colombia, Bolivia) where soil Cd levels are naturally elevated [Ref 25, 37]. 
- Mean Cd concentrations in commercial cocoa powder: ~0.08 mg/kg (Iran study) [Ref 36]
- EU cadmium limit: 0.3 mg/kg for cocoa powder; 0.1 mg/kg for milk chocolate
- Dark chocolate contains higher Cd than milk or white chocolate due to higher cocoa content [Ref 26]
- Cadmium has a biological half-life of 10–30 years and accumulates in kidney; poses heightened risk for children who are primary chocolate consumers [Ref 26, 37]

**Lead (Pb):** Documented at measurable levels in dark chocolate; some samples exceed international limits. Contamination largely post-harvest from environmental deposition during drying [Ref 25]. Disproportionate risk to Black and Hispanic children due to already-higher environmental lead exposures [Ref 26].

**Arsenic (As):** Detected in cocoa powder at 0.06 mg/kg mean concentration (within ISO standards in one study) [Ref 36].

**Pesticide residue:** Not covered in retrieved literature — ⚠️ FLAG (gap).

### Contraindications and Vulnerable Populations

**Pregnancy:** Caffeine in cocoa is a relevant exposure concern. Meta-analysis of 60 studies: each 100mg caffeine increment associated with 14% increase in spontaneous abortion risk, 19% increase in stillbirth risk, and 10% increase in SGA birth risk [Ref 30]. UK NHS and WHO recommend ≤200mg caffeine/day during pregnancy; heavy dark chocolate consumption could contribute meaningfully to this limit.

**Pediatric use:** Cadmium accumulation risk is heightened in children; dark chocolate is not recommended as a primary food for young children due to heavy metal content [Ref 26].

**Dogs and cats:** Theobromine is severely toxic in companion animals due to slow elimination; any cocoa/chocolate consumption warrants veterinary evaluation [Ref 40].

**Hepatic impairment:** CYP1A2 is hepatically expressed; impaired liver function will reduce caffeine and theobromine clearance. No cocoa-specific hepatic safety data retrieved.

**MAO inhibitor users:** Theoretical tyramine/PEA risk (see Herb-Drug Interactions above) — FLAG.

---

## Harm Reduction

- Individuals on irreversible MAO inhibitors (phenelzine, tranylcypromine) should be counseled about potential tyramine/phenylethylamine content in chocolate, though published case reports specifically implicating cocoa are absent
- Pregnant individuals should count dark chocolate toward daily caffeine limits; 100g dark chocolate ≈ 40–80mg caffeine
- Cadmium exposure can be reduced by choosing milk chocolate (lower cocoa content) or limiting dark chocolate consumption frequency; preference for chocolates from West African origin (Ghana, Ivory Coast) where soil Cd is lower than Latin American origins [Ref 25]
- Heavy daily dark chocolate consumption can contribute to caffeine dependence; gradual reduction is preferred over abrupt cessation to avoid withdrawal headache
- Theobromine toxicity in pets is severe — household cocoa products should be kept inaccessible to dogs and cats [Ref 40]
- No standardized chemical testing regime for dietary cocoa products exists in most jurisdictions; cadmium content is not commonly disclosed on consumer labels

---

## Legal Status

**International:** *Theobroma cacao* and its products (cocoa, chocolate) are not listed in any United Nations drug control conventions (1961 Single Convention on Narcotic Drugs, 1971 Convention on Psychotropic Substances, 1988 Convention Against Illicit Traffic in Narcotic Drugs). Theobromine and caffeine are similarly unscheduled internationally [Ref — WebSearch legal status].

**Regulatory status globally:** Cocoa is regulated exclusively as a food commodity:
- **EU:** Directive 2000/36/EC harmonizes composition requirements; "Chocolate" ≥35% total dry cocoa solids; "Milk Chocolate" ≥25% cocoa solids [Ref — WebSearch EU law]
- **International:** Codex Alimentarius CODEX STAN 87-1981 (voluntary standard)
- **EU Deforestation Regulation:** Effective December 2024, cocoa products sold in or exported from the EU must demonstrate they are not produced on land deforested or degraded after December 2020 [Ref — WebSearch]
- **US:** FDA regulates cocoa/chocolate as food; standard of identity requirements exist for chocolate labeling; no DEA scheduling
- **Australia, Canada, UK:** No scheduling; regulated as food

**Alkaloid scheduling note:** Caffeine is listed under special monitoring by WADA in sports contexts (not prohibited, but monitored). Theobromine and phenylethylamine are unscheduled in all jurisdictions reviewed. ⚠️ FLAG for human review: Confirm jurisdiction-specific details with regulatory databases for edge cases.

---

## Clinical Trials

| NCT ID | Title / Focus | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT03035201 | COSMOS-Mind: Cocoa flavanols (500mg/day) for cognitive outcomes in older adults | Completed | — | Wake Forest U Health Sciences |
| NCT04582617 | Effects of cocoa flavanols on cognition (online assessment) | Completed | — | Columbia University |
| NCT03723694 | Dietary modulation of neuroinflammation and memory | Completed | — | Columbia University |
| NCT04374409 | Acute cocoa flavanols: cerebral oxygenation and cognition | Completed | — | University of Birmingham |
| NCT02943096 | Flavanol augmentation for antidepressant non-responsive late-life depression | Terminated | — | NY State Psychiatric Institute |

Key published result: COSMOS-Mind (NCT03035201) tested 500mg/day cocoa flavanols vs placebo in older women and men for cognitive protection (published in *Alzheimer's & Dementia*, 2023) [Ref 43]. Full results data not extractable from truncated abstract — ⚠️ FLAG: generation agent should verify primary results.

---

## Community Feedback Analysis

No community feedback submitted for this substance (Part A2 of brief was empty).

---

## Gaps & Flags

### Data Absent from Published Literature (API-accessible)
1. **Human LD50 for theobromine:** No primary published study retrieved. Secondary sources estimate ~1000 mg/kg but this cannot be api-verified. ⚠️ Flag dose values as unverified.
2. **Theobromine half-life (primary PK study):** Secondary review papers cite ~6–10h but no primary human PK study specifically for theobromine was retrieved.
3. **CYP enzyme involvement for theobromine:** Caffeine CYP1A2 metabolism well documented; theobromine-specific CYP kinetics not retrieved.
4. **Dose tiers (threshold/common/heavy) for cocoa preparations:** No published dose-finding studies characterizing psychoactive dose thresholds for cocoa as a preparation exist. All dose data in "Effects & Dose" section is ⚠️ flagged for human review.
5. **Pesticide/mycotoxin contamination in cocoa:** Not covered in retrieved literature.
6. **Phenylethylamine quantified content in cocoa/chocolate:** No HPLC quantification study retrieved from API searches specifically for PEA in chocolate.

### Contradictions Between Sources
- The brief classifies cocoa as a "preparation" (PSX type field), which is accurate for processed cocoa products but not for the source plant. The generation agent should clarify whether the article covers the plant (*T. cacao*) or the processed preparation, or both.
- Some seed effects (motivation-suppression, thought-deceleration, depression) are not well supported by published pharmacological or clinical evidence at typical dietary doses. These should be flagged if assigned intensity/frequency values.

### Sections with Traditional-Use Accounts as Primary Evidence ⚠️ Flag for Human Review
- Ceremonial and spiritual use of cacao in pre-Columbian Mesoamerica (Maya, Aztec): historical/archaeological evidence is the primary source; no clinical confirmation
- Preparation methods of traditional xocolatl beverages: ethnographic accounts are the primary evidence

### Herb-Drug Interaction Severity: Not Backed by Clinical Case Reports
- MAOI + chocolate tyramine/phenylethylamine: theoretically plausible but no published case reports identified ⚠️ Flag
- All other interaction severities not backed by primary clinical literature

### Unresolved Issues
- Whether the "ceremonial cacao" preparations gaining popularity in wellness communities (high-dose cacao paste/ceremony) produce meaningfully different psychoactive effects compared to standard dietary chocolate requires clinical investigation; no published data found
- COSMOS-Mind primary results (cognitive outcomes) need full extraction — abstract was truncated in API response

### Effect Seed Data Assessment (for generation agent)
Based on evidence gathered, the following effects have pharmacological support at dietary doses:
- **stimulation** [body]: Supported — methylxanthine mechanism; intensity likely low at typical doses
- **wakefulness** [body]: Supported — adenosine A1R blockade; intensity likely low-moderate at typical doses
- **cognitive-euphoria** [thinking]: Weakly supported — mood improvement in some RCTs; intensity likely low
- **motivation-enhancement** [thinking]: Weakly supported — methylxanthine-mediated; intensity likely low
- **thought-acceleration** [thinking]: Weakly supported — caffeine at higher doses; intensity very low
- **anxiety** [feeling]: Supported at higher intakes — caffeine-induced; frequency low at typical doses
- **headache** [body]: Primarily a withdrawal phenomenon from cessation, not acute use; frequency low
- **vasoconstriction** [body]: Complex — caffeine is vasoconstrictive but theobromine and flavanols are vasodilatory; net effect is likely vasodilation at typical doses. Assignment of "vasoconstriction" to cocoa is pharmacologically questionable — ⚠️ Flag for editorial review
- **nausea** [body]: Possible at high dark chocolate intake; frequency low
- **abnormal-heartbeat** [body]: Possible at high caffeine doses; frequency very low at dietary doses

The following seed effects have **minimal or no pharmacological support** at typical dietary doses and should be assigned low/very low intensity if included at all:
- excessive-sweating, pupil-dilation, spontaneous-body-sensations, cognitive-fatigue, motivation-suppression, novelty-enhancement, thought-deceleration, depression, irritability, disinhibition